Australia's most trusted
source of pharma news
Posted 28 October 2024 AM
Cell and gene therapy company RhemaGen Australia which is engineering a new class of therapeutics for major autoimmune diseases, has nabbed two high-profile names in Australian industry with ex-Janssen Managing Director Bruce Goodwin and ex-ARCS CEO Shanny Dyer joining the board.
RheumaGen's lead program, RG0401, is designed as a one-time curative treatment for rheumatoid arthritis (RA). The Australian arm of the business will be responsible for advancing the HLA gene-edited cell therapy for refractory RA to a Phase I clinical trial in Australia and for commercialising HLA gene-edited cell therapies for rheumatoid arthritis locally.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.